Articles related to OVARIAN CANCER

An ESMO express update to epithelial ovarian cancer guidelines added rucaparib and mirvetuximab soravtansine as treatment options, but expert commentary and two subsequent FDA approvals have raised questions about the update’s current clinical applicability.

Treatment options for platinum‑resistant ovarian cancer remain limited. New phase 3 survival data suggest that adding a novel agent to standard chemotherapy may meaningfully extend survival for this hard‑to‑treat population.

Referral rates for newly diagnosed gynecological malignancy occurred in only 14.6% of eligible patients despite attendance rates of 81.7% when referrals were made.

In mice whose immune cells that lack the ability to recognize flagellin, immune therapy induced long-term control of ovarian tumor growth in almost 80% of animals.

Comprehensive genetic profiling now plays a central role in ovarian cancer management, with mandatory offering of both germline and somatic testing for all patients at diagnosis.

Mirvetuximab soravtansine represents a pivotal shift in treating platinum-resistant ovarian cancer, demonstrating not only improved survival outcomes but also a higher response rate compared to standard chemotherapy.